2013 Innovation Impact



AAMDSThe Aplastic Anemia & MDS International Foundation received the hematology Innovation Impact Award for the MDS Clinical Research Consortium.? Established in July 2012, the MDS Clinical Research Consortium is an unprecedented collaboration of the six largest MDS centers in the U.S. and is designed to undertake unique studies and trials to advance treatments and improve outcomes for patients with Myelodysplastic Syndromes (MDS). The Consortium enlists multiple MDS clinical research centers and fills a major gap in MDS-related clinical research in the United States by providing a new “critical mass” of patients and patient data to support the evaluation of promising new compounds, epidemiological studies, and translational studies leading to new classifications, treatments, and procedures. In this collaborative environment, enhanced by expanded access to patient data, tissue samples, and the use of a standardized patient work-up, research leading to potentially beneficial outcomes for patients is accelerated.

“Even from the earliest stages of development , we believed that the MDS Clinical Research Consortium was an innovative , game changing project that was perfectly aligned with our strategic plan.? It is exciting –and humbling—to see that others are seeing it in the same way. We are very pleased and honored to be selected for this new and prestigious award.? We deeply appreciate the support of the Edward P. Evans? Foundation and our six Consortium partners who have made this program possible and for the hope it brings to patients and families for new treatments and a cure for MDS. “–John Huber, Executive Director, AA&MDSIF



Lung cancer allianceThe Lung Cancer Alliance (LCA) received the oncology Innovation Impact Award for the “National Framework for Excellence in Lung Cancer Screening and Continuum of Care” initiative.? This first of its kind? national framework for lung cancer screening is a collaborative approach to breaking through the status quo of lung cancer and positively impacting the 15% survival rate which has barely changed in forty years.? LCA convened thought leaders from all fields related to lung cancer in 2012 to devise the “National Framework”, which has since been adopted by more than 100 medical facilities nationwide and endorsed by numerous professional societies.? Funding from the award will help support efforts to educate the at-risk public through an award winning awareness campaign, encouraging more medical facilities to adopt the National Framework and implement its best practices and guidelines, and improving and expanding lung cancer screening.

“We are absolutely honored and thrilled to receive this prestigious award. ?We thank Celgene and the award committee for acknowledging the lifesaving impact of our National Framework of Excellence for Lung Cancer Screening and Continuum of Care. This means so much to our staff, the more than 100 screening centers of excellence following the Framework and most importantly, for those individuals diagnosed with or at risk for lung cancer.? This is a proud moment and renews our commitment to saving lives through helping the community, advancing screening and accelerating lung cancer research.–Laurie Fenton Ambrose, President and CEO, Lung Cancer Alliance



Awards Program for US residents only